RARS1 and cancer: In cancer cells, activation of RARs by retinoid agonists promotes the transcription of different molecular mediators that can activate several pathways, including apoptosis, cell cycle arrest, differentiation, modulation of key inflammatory mediators of the immune system, activation of kinase pathways, and epigenetic modifications on the level of enzymes and miRNA (Fig. 1) [12, 13].